Hong Zhang

发表

A biochemical rationale for the anticancer effects of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analogues

A. King, R. Copeland, P. Tummino, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Assay Development and High-Throughput Screening of Small Molecular c-Abl Kinase Activators

Chad Quinn, R. Ames, G. Hofmann, 2011, Journal of biomolecular screening.

A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination.

R. Copeland, K. Auger, P. Tummino, 2006, Biochemistry.

Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFD.

K. Alitalo, A. Anisimov, Harri J Nurmi, 2016, The Journal of clinical investigation.

Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction.

Neysa Nevins, D. Mcnulty, A. Gilmartin, 2014, Nature chemical biology.

Microsecond molecular dynamics simulations provide insight into the ATP‐competitive inhibitor‐induced allosteric protection of Akt kinase phosphorylation

Shaoyong Lu, Zhanxiu Cai, Linkai Mou, 2017, Chemical biology & drug design.

Development of a high-throughput screen to detect inhibitors of TRPS1 sumoylation.

Susheel Kumar, T. Meek, L. Szewczuk, 2013, Assay and drug development technologies.

Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site.

Yoshiaki Washio, Junya Qu, Thau Ho, 2011, Chemistry & biology.

Structure-guided optimization of small molecule c-Abl activators

Ping Cao, Jingsong Yang, Hong Zhang, 2014, Journal of Computer-Aided Molecular Design.

Reverse Hydroxamate Inhibitors of Bone Morphogenetic Protein 1.

R. A. Reid, D. Holt, R. Gampe, 2018, ACS medicinal chemistry letters.

Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site.

M. Head, S. Moores, G. Hofmann, 2011, Chemistry & biology.